Drug compounders sue FDA over semaglutide status

Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's weight-loss and diabetes treatments Wegovy and Ozempic from its shortage list,
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group has sued the U.
Drug compounders sue FDA over declaration ending Wegovy shortage
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” but in earnings Monday still forecast higher revenue and profits in 2025.
Off-brand weight-loss drug makers are suing the FDA, again
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another lawsuit against the U.S. Food and Drug Administration (FDA). This time, it’s over the health regulator’s decision to remove semaglutide — the active ingredient in Novo Nordisk’s (NVO) popular Ozempic and Wegovy treatments — from its drug shortage list.
ScienceAlert on MSN6h
FDA Will Finally Ban Controversial Ingredient in Popular Decongestants
Sudafed, Mucinex, Benadryl, Advil, Tylenol, Vicks, and Dimetapp. These popular brand names appear on oral decongestants that ...
US FDA issues labeling changes for testosterone products
The U.S. Food and Drug Administration said on Friday it issued new labeling changes for testosterone products based on ...
Pharm Exec9h
FDA Approves Investigational New Drug Application for Fapon Biopharma’s Novel Immunotherapy for Solid Tumors
FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.
BioSpace13h
6 Rare Diseases That Have New FDA-Approved Treatments
ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...
Endocrinology Advisor1d
FDA Alert: Endocrinology Drug News Roundup 2025
FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...
Pfizer Names Former FDA Drug Chief as Top Doctor
Pfizer Inc. appointed the Food and Drug Administration’s former top drug reviewer to serve as its chief medical officer.
The American Journal of Managed Care10h
5 Rare Diseases That Now Have Their First FDA-Approved Treatments
Several rare disease patient populations received their first-ever FDA-approved drug since Rare Disease Day last year, ...
MedPage Today8d
FDA Approves First Drug for Rare Lipid Storage Disorder
Chenodiol -- a naturally occurring human bile acid also known as chenodeoxycholic acid -- is the first FDA-approved drug indicated for the rare lipid storage disease and autosomal recessive ...
FDA approves new opioid-free painkiller
Neurosurgeon and scientist Dr. Jandial joined us to discuss a major breakthrough in pain medication recently approved by the ...